Lucentis®
Lucentis® is a biological therapy with 37 clinical trials. Currently 1 active trials ongoing. Historical success rate of 89.7%.
Success Metrics
Based on 26 completed trials
Phase Distribution
Phase Distribution
7
Early Stage
7
Mid Stage
14
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
86.7%
26 of 30 finished
13.3%
4 ended early
1
trials recruiting
37
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration
Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity
ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
Clinical Trials (37)
Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration
Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity
ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD
A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration
Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®
Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis
A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD
Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects
A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration
Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
Anti-VEGF Intravitreous Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery
French Evaluation Group Avastin Versus Lucentis
Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 37